Edge Therapeutics (NASDAQ:EDGE) was downgraded by BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Tuesday.

Separately, Zacks Investment Research raised shares of Edge Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th.

Edge Therapeutics (NASDAQ EDGE) traded down $0.10 during midday trading on Tuesday, hitting $9.14. 46,829 shares of the company traded hands, compared to its average volume of 62,649. The company has a debt-to-equity ratio of 0.20, a current ratio of 8.34 and a quick ratio of 8.34. Edge Therapeutics has a 1 year low of $7.30 and a 1 year high of $13.50.

Edge Therapeutics (NASDAQ:EDGE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.11. research analysts forecast that Edge Therapeutics will post -1.7 earnings per share for the current fiscal year.

In other Edge Therapeutics news, insider Brian A. Leuthner sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $9.86, for a total transaction of $73,950.00. Following the sale, the insider now owns 95,236 shares of the company’s stock, valued at approximately $939,026.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Brian A. Leuthner sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $10.93, for a total transaction of $27,325.00. Following the sale, the chief executive officer now directly owns 110,236 shares in the company, valued at approximately $1,204,879.48. The disclosure for this sale can be found here. In the last three months, insiders have sold 35,861 shares of company stock worth $378,035. 36.19% of the stock is owned by insiders.

A number of large investors have recently added to or reduced their stakes in EDGE. Voya Investment Management LLC purchased a new stake in shares of Edge Therapeutics in the 2nd quarter valued at $106,000. Russell Investments Group Ltd. boosted its holdings in shares of Edge Therapeutics by 16.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,959 shares of the biotechnology company’s stock valued at $123,000 after acquiring an additional 1,733 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Edge Therapeutics in the 3rd quarter valued at $130,000. State of Wisconsin Investment Board purchased a new stake in shares of Edge Therapeutics in the 2nd quarter valued at $154,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Edge Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,114 shares of the biotechnology company’s stock valued at $186,000 after acquiring an additional 3,764 shares during the last quarter. 50.26% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/12/edge-therapeutics-edge-downgraded-to-strong-sell-at-bidaskclub.html.

About Edge Therapeutics

Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.

Receive News & Ratings for Edge Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.